You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Nanoscience as a tool to improve CNS drugs
The blood-brain barrier has for a long time been an obstacle for the delivery of drugs to the brain, especially for drugs targeting the central nervous system. Additionally the bioavailability of these drugs can be quite low after oral intake, creating a need for high doses to reach sufficient effectiveness. This project aims to develop new formulation strategies for improving bioavailability and increasing brain penetration of new CNS-active drugs.
Nanoscience, the use and modification of particles on a nanoscale, is promising to be an excellent tool to achieve these goals. The approach is multi-disciplinary, combining distinct disciplines such as pharmaceutical technology, chemistry, cell biology, pharmacology, and diagnostic (PET-imaging) in one research team. Underlying goals are to determine the influence and interplay of absorption, transporters, metabolizing enzymes and targeting on drug deposition and hence accurately define the optimal process for the development of new drugs. The result of the obtained knowledge will be less invasive and more specific methods of tackling CNS disorders.
Full project title: Nanoscience as a tool for improving bioavailability and blood-brain barrier penetration of CNS drugs
Start date: January 2007
End date: January 2012
Goal: Increase bioavailability and brain penetration of new central nervous system drugs
Principal investigator: Heike Dinter-Heidoorn
Project size: 9,7 FTE's
Partners: Abbott, Leiden University, Radboud University Nijmegen, Radboud University Nijmegen Medical Centre, University Medical Center Groningen, University of Groningen, Utrecht University
Hanneke Wittgen (project T5-105)
The role of brain and intestinal efflux transporters in disposition of central nervous system drugs
Joost Westerhout (project T5-105)
Prediction of Brain Target Site Concentrations on the Basis of CSF PK